glp-1 trump administration makes deal to lower prices The Trump Administration is delivering

A provider should reassess progress, side effects, hormone markers, metabolic health, and whether the peptide should be continued, adjusted, paused, or stopped

The standard retatrutide dose schedule is: Weeks 1-4: 1 mg once weekly Weeks 5-8: 2 mg once weekly Weeks 9-12: 4 mg once weekly Weeks 13-16: 8 mg once weekly Week 17 onward: 8-12 mg once weekly (maintenance) In the combination context, many researchers find that 8 mg is sufficient for their maintenance dose rather than pushing to 12 mg, because the cagrilintide provides enough additional appetite suppression and satiety to make the extra 4 mg of retatrutide unnecessary

Potential conflict of interest to note: Several of the study authors worked for the company who produced the product used in the study

Most patients notice reduced appetite within the first week

This allows the body to use fat stores as fuel, increasing energy levels and endurance during workouts

"All Americans, even those who are not on Medicaid, Medicare, are going to be able to get the same price for their drugs, for their GLP-1s." 1 Clinicians are Cautiously Optimistic Physicians treating obesity have welcomed the announcement with measured optimism